Inhibitory effects of SR141716A on G-protein activation in rat brain

European Journal of Pharmacology

Volumn 414, Issue 2-3, 2001, Pages 135-143

  Sim Selley, Laura J ^a   Brunk, Leah K ^a   Selley, Dana E ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cannabinoid receptor; G protein coupled receptor; 35S GTP S binding

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID RECEPTOR ANTAGONIST; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE TRIPHOSPHATE; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING SITE; BRAIN; BRAIN REGION; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INHIBITION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; RECEPTOR BINDING; RECEPTOR DENSITY;

ANIMALS; BORNANES; BRAIN; CALCIUM CHANNEL BLOCKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; GTP-BINDING PROTEINS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); MALE; MORPHOLINES; NAPHTHALENES; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; SODIUM CHLORIDE;

EID: 0035794019     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(01)00784-1     Document Type: Article

References (47)

1. 1
2. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1
3. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding
4. Regional differences in cannabinoid receptor/G-protein coupling in rat brain
5. 35S]GTPgS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity
6. 9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptor-activated G-proteins in brain
7. Effects of anandamide on cannabinoid receptors in rat brain membranes
8. Appetite suppression and weight loss after the cannabinoid antagonist SR141716A
9. Cannabinoid modulation of intestinal propulsion in mice
10. In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): Inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity
11. Spontaneous association between opioid receptors and GTP-binding proteins in native membranes: Specific regulation by antagonists and sodium ions
12. Comparison of novel cannabinoid partial agonists and SR141716A in the guinea-pig small intestine
13. Determination and characterization of a cannabinoid receptor in rat brain
14. Cannabinoid pharmacology
15. Isolation, structure, and partial synthesis of an active constituent of hashish
16. Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A
17. Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A
18. 2 receptors
19. 2 receptor absence in the rat central nervous system
20. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study
21. Agonist-independent inhibition of G protein activation by muscarinic acetylcholine receptor antagonists in cardiac membranes
22. Muscarinic acetylcholine receptor-stimulated binding of guanosine 5′-O-(3-thiotriphosphate) to guanine-nucleotide-binding proteins in cardiac membranes
23. Effects of CB(1) cannabinoid receptor activation on cerebellar granule cell nitric oxide synthase activitym
24. Health aspects of Cannabis
25. 1 receptors
26. 1 receptor
27. 2 receptors
28. Cannabinoid receptors can activate and inhibit G protein-coupled inwardly rectifying potassium channels in a xenopus oocyte expression system
29. Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H- pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxylic acid phenylamide (CP-272871) for the CB(1) cannabinoid receptor
30. βγ subunits of guanine nucleotide-binding proteins and regulation of spontaneous receptor activity: Thermodynamic model for the interaction between receptors and guanine nucleotide-binding protein subunits
31. Differential requirements of sodium for coupling of cannabinoid receptors to adenylyl cyclase in rat brain membranes
32. 1 cannabinoid receptor activity
33. 1 receptors in mouse urinary bladder
34. SR144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist
35. SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice
36. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
37. In vivo characterization of the specific cannabinoid receptor antagonist, SR141716A: Behavioral and cellular responses after acute and chronic treatments
38. 35S]thio)triphosphate binding in rat brain membranes
39. 1 antagonist SR141716A
40. 2): Identification of cannabinoid receptor subtype selective ligands
41. 35S]thio]-triphosphate binding
42. 35S]GTPγS autoradiography in rat brain
43. 35S]GTPγS autoradiography in rat brain
44. A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2
45. Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity
46. 1 cannabinoid receptor antagonist, SR141716
47. 2-adrenergic receptor activation of G proteins: Evidence for a precoupled receptor/G protein state